CSL Limited makes many of its therapies from donated plasma, which posed a challenge as pandemic lockdowns led to a steep drop in plasma collections. In acquiring Vifor Pharma, CSL not only diversifies, it also expands its presence in the fast-growing nephrology market.
Talecris Biotherapeutics shareholders will spend Valentine's Day voting whether to approve the $3.4 billion offer from Spanish company Grifols to buy the company. But the merger faces a more important test. The Federal Trade Commission could still block the deal on antitrust grounds as it did two years ago when CSL Limited tried to buy Research Triangle Park-based Talecris.
This eBook provides actionable strategies, real-world best practices to help payers stay ahead in a value-based care environment.